Natera, Inc.
NTRA
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $47.0B
$328.18
▲ +0.16%
P/E
-241.31
Mkt Cap
$47.0B
52-Wk Range
$157.43–$343.18
52-Week Range
$157.43 - $343.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 95.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary cell-free DNA testing technology with established clinical validation
- Comprehensive product portfolio spanning prenatal, reproductive, oncology, and transplant diagnostics
- Extensive distribution network of 100+ laboratory partners enabling broad market access
- Strategic partnerships with BGI Genomics and Foundation Medicine for product development
- Cloud-based Constellation platform creating recurring revenue and customer lock-in
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Stable outlook
Expanding adoption of non-invasive prenatal testing (NIPT) as standard of care in obstetrics
Value
Trading at 0.0x Life Sciences Tools peers — a discount despite the growth profile.
Momentum
Hot
+52.4% over 3m
Quality
Excellent
High-growth business (38% revenue growth, 65% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying NTRA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.47 vs -$0.49 consensus (+4.8% surprise). Revenue of $752.8M vs $661.2M expected (+13.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+4.8%
Revenue trend · last 8Q
—
+53%
+36%
+32%
+35%
+40%
+39%
+38%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$439.8M
$476.1M
$501.8M
$546.6M
$592.2M
$665.5M
$696.6M
$752.8M
Margins · last 8Q
Gross
64.6%
Operating
-10.1%
Profit
-8.9%
Wall Street consensus
10 analysts · 90% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
90%
Hold
10%
Sell
0%
Median Price Target
$290.00
▼ -11.6% vs $328.18
Latest: Guggenheim · Aug 12, 2026
1 analyst covering
vs Industry
How NTRA stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related